Kryxana 200mg Tablet

Metastatic ​Breast Cancer

Most side effects of Kryxana 200mg Tablet do not require medical attention as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately.
Seizures  
Vomiting  
Diarrhea  
Chest tightness  
Stomach pain  
Nausea 
Unusual tiredness  
Itching 
Changed sense of taste
Trouble sleeping
Headache
Decreased white blood cell count
Back pain
Tingling of hands and feet

​Take Kryxana 200mg Tablet as prescribed by your doctor. Do not stop or skip your regular dosing schedule. In case of an overdose of Kryxana Tablet, consult your doctor immediately for emergency medical treatment.  

Ribociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6. These kinases are activated upon binding to D-cyclins and play a crucial role in signaling pathways that lead to cell cycle progression and cellular proliferation. After the oral administration, the effect of Kryxana 200mg Tablet can be observed in 2 to 4 hours. This slows the growth of cancer cells and eventually kills them.

​If you forget to take a dose of Kryxana Tablet, consult your doctor. Don’t double up the next dose to cope with the missed one unless your doctor recommends it.​​

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

Abdelmalak, M., Singh, R., Anwer, M., et al. (2022). The renaissance of CDK inhibitors in breast cancer therapy: An update on clinical trials and therapy resistance. Cancers, 14(21), 5388.

Dajsakdipon, T., Susiriwatananont, T., Wongkraisri, C., Ithimakin, S., Parinyanitikul, N., Supavavej, A., & TSCO Breast Oncology Group. (2024). Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus aromatase inhibitor in HR+/HER2− advanced breast cancer: Preliminary real‑world data from Thailand. BMC Cancer, 24(1), 1018.

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., … Goetz, M. P. (2022). Overall survival with ribociclib plus letrozole in advanced breast cancer. New England Journal of Medicine, 386(18), 942–950.

Ji, Y., Yartsev, V., Quinlan, M., Serra, P., Wang, Y., Chakraborty, A., & Miller, M. (2023). Justifying ribociclib dose in patients with advanced breast cancer with renal impairment based on PK, safety, and efficacy data: An innovative approach integrating data from a dedicated renal impairment study and oncology clinical trials. Clinical Pharmacokinetics, 62(3), 493–504.

Xu, J., Wang, R., & Shen, K. (2025). A post-marketing disproportionality analysis of the safety of ribociclib based on the FDA Adverse Event Reporting System. Therapeutic Advances in Drug Safety, 16, 20420986251324633.